C9ORF72 repeats create RNA foci and dipeptide aggregates in mice, but antisense oligonucleotides suppress them.
Two new papers rekindle acrimonious debate about exactly what “loss-of-function” means when it comes to presenilin mutations in Alzheimer’s pathogenesis.
Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
Frontotemporal Dementia Study Group Workshop: Building an Infrastructure to Support FTLD Therapeutic Development
Drug Trials in Frontotemporal Dementia: Can Field Push Forward Together? WANTED: Biomarkers for Drug Trials in Frontotemporal Dementia Regulators Tell Frontotemporal Dementia Community: We Play on Your Team Earlier this month in Washington, D.C., 95 ...
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
By examining polymorphisms linked to autoimmune diseases, researchers pinned two loci to Alzheimer’s risk. Both may worsen neurofibrillary tangle pathology.
Exome sequencing in families with amyotrophic lateral sclerosis and frontotemporal dementia yields variants of a gene that helps recycle cellular waste.
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
Researchers confirm that new cases of dementia are on the wane in the United Kingdom, with the greatest benefits among older men.
A bit less strapped for funding, researchers are considering the next steps for Lewy body, frontotemporal, and vascular dementia.
AD-Related Dementias Summit 2016: Progress, Aims, Dollars At 2016 Summit, Field Tackles AD-Related Dementias One By One Did you know the U.S. National Alzheimer’s Project Act covers Lewy body, frontotemporal, vascular, and mixed dementias, as well? It ...
NAPA's latest collective exercise was a conference to update the field on progress in the past three years and advise the NIH on how to spend the next round of funds.
Neurogeneticists honored for their discoveries, especially of repeat expansions that cause ALS/FTD.
Scientists report that the transcription factor NRF2 regulates tau expression, stimulating production of a protective isoform.
A NOVA special gets up close and personal with Alzheimer’s researchers and their patients, asking if this disease can be stopped.